Pharmaceutical News

RSS

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

Cell Therapeutics, Inc. announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

Department of Health reminds at-risk Pennsylvanians to receive H1N1 vaccination

The federal Centers for Disease Control and Prevention, or CDC, has allocated a total of 2,940,300 doses of H1N1 flu vaccine to Pennsylvania to date, the state Department of Health said today.

8 Dec 2009

Erbitux gaining market share of Avastin in Europe

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

8 Dec 2009

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

Results of two new studies support the use of the intravenous formulation of the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy in clinical settings where oral AED therapy is temporarily not feasible.

8 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Generic erosion of premium-priced branded agents to offset sales of new agents

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

8 Dec 2009

Market for personalized medicine in the United States to grow 11 percent annually, shows report

The market for personalized medicine in the United States is already $232 billion, and it is projected to grow 11 percent annually, according to a new report published today by PricewaterhouseCoopers LLP, entitled The Science of Personalized Medicine: Translating the Promise into Practice.

8 Dec 2009

Vitamins and nutriceuticals improve memory and cognitive performance, shows study

A recent study presented at the Gerontological Society of America's 62nd Annual Scientific Meeting shows that a combination of vitamins and nutriceuticals improves memory and cognitive performance in community-dwelling adults.

8 Dec 2009

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.

8 Dec 2009

JAK2 inhibitor can control myelofibrosis, report researchers

A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium.

8 Dec 2009

Defibrotide drug effective against hepatic veno-occlusive disease

Defibrotide, a novel drug which modulates the response of blood vessels to injury, was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease, a life threatening toxicity of transplant caused by blockages in tiny blood vessels of the liver, according to a study led by Dana-Farber Cancer Institute scientists.

8 Dec 2009

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Novo Nordisk A/S and ZymoGenetics, Inc. today announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, as well as broad intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.

From Novo Nordisk 8 Dec 2009

Deaths from opioid use in Ontario have doubled, according to new study

Deaths from opioid use in Ontario have doubled-from 13.7 deaths per million residents in 1991 to 27.2 deaths per million residents in 2004-according to a new study led by physicians at St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES) in Toronto.

8 Dec 2009

PolyMedix to present data on its heptagonist compounds

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.

8 Dec 2009

Selenium-based antioxidant compound reduces risk of colorectal cancer

Supplementation with a selenium-based antioxidant compound decreased the risk of developing new polyps of the large bowel — called colorectal metachronous adenomas — in people who previously had colorectal polyps removed.

8 Dec 2009

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

A targeted drug that is active against acute myeloid leukemia (AML) is particularly effective when teamed with chemotherapy in patients whose cancer cells harbor a key genetic mutation, researchers at Dana-Farber Cancer Institute and their colleagues will report at the American Society of Hematology's (ASH) annual meeting on Monday, Dec. 7 (Ernest N. Morial Convention Center, Room 343-345, 5:15 pm CT).

8 Dec 2009

Pharmaceutical News

Pixantrone demonstrates substantial reduction in cardiac cell toxicity compared to anthracyclines

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Department of Health reminds at-risk Pennsylvanians to receive H1N1 vaccination

Erbitux gaining market share of Avastin in Europe

CML patients on nilotinib or dasatinib drug achieve better response than imatinib drug

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

Specialty pharmaceutical market: Treatment patterns and product performance

Generic erosion of premium-priced branded agents to offset sales of new agents

Market for personalized medicine in the United States to grow 11 percent annually, shows report

Vitamins and nutriceuticals improve memory and cognitive performance, shows study

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

JAK2 inhibitor can control myelofibrosis, report researchers

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

Defibrotide drug effective against hepatic veno-occlusive disease

Novo Nordisk in-licenses intellectual property rights to IL-21 antibodies

Deaths from opioid use in Ontario have doubled, according to new study

PolyMedix to present data on its heptagonist compounds

Selenium-based antioxidant compound reduces risk of colorectal cancer

Combination of chemotherapy and midostaurin drug may benefit AML patients with FLT3 mutations

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News